DOCSLIB.ORG

Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopa

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopa REVIEW Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopamine in the Prefrontal Cortex Charles R. Yang, Ph.D., Jeremy K. Seamans, Ph.D., and Natalia Gorelova, Ph.D. This review covers some recent findings of the same schizophrenic patient in the course of the illness. We electrophysiological mechanisms through which hypothesize that the dysfunctional mesocortical dopamine mesocortical dopamine modulates prefrontal cortical input to the PFC may lead to abnormal modulation of neurons. Dopamine has been shown to modulate several ionic channels distributed in the dendritic–somatic ionic conductances located along the soma-dendritic axis of compartments of PFC pyramidal neurons that project to the prefrontal cortical pyramidal neurons. These ionic currents ventral tegmental area and/or nucleus accumbens. In some include high-voltage-activated calcium currents and slowly schizophrenics, a reduction of mesocortical dopamine to inactivating Na1 and K1 currents. They contribute actively below optimal levels and/or a loss of local GABAergic in processing functionally segregated inputs during inputs may result in a dysfunctional integration of extrinsic synaptic integration. In addition, dopamine mainly associative inputs by Ca21 channel activity in the distal depolarizes the fast-spiking subtype of local GABAergic dendrites of PFC pyramidal neurons. This may account for interneurons that connect the pyramidal neurons. This the patients’ distractibility caused by their inability to focus latter action can indirectly control pyramidal cell only on relevant external inputs. In contrast, in acute stress excitability. These electrophysiological data indicate that the or psychotic episodes, an associated abnormal elevation of actions of dopamine are neither “excitatory” nor mesocortical dopamine transmission may greatly influence “inhibitory” in pyramidal prefrontal cortex neurons. distal dendritic Ca21 channel-mediated signal-processing Rather, the actions of dopamine are dependent on soma- mechanisms. This can enhance possible reverberative dendritic loci, timing of the arrival of synaptic inputs, activity between adjacent interconnected pyramidal strength of synaptic inputs, as well as the membrane neurons via the effects of dopamine on the slowly potential range at which the PFC neuron is operating at a inactivating Na1, K1, and soma-dendritic Ca21 currents. given moment. Based on available electrophysiological The effects of high levels of PFC dopamine in this case may findings, a neuronal model of the pathophysiology of contribute to behavioral perseveration and stereotypy so schizophrenia is presented. This model proposes that that the patients are unable to use new external cues to episodic hypo- and hyperactivity of the PFC and the modify ongoing behaviors. [Neuropsychopharmacology associated dysfunctional mesocortical dopamine system 21:161–194, 1999] © 1999 American College of (and their interconnected brain regions) may coexist in the Neuropsychopharmacology. Published by Elsevier Science Inc. From the Neuroscience Research (CRY), DC 0510, Eli Lilly & Address correspondence to: C. Y. Yang, Ph.D., Eli Lilly and Com- Company, Lilly Corporate Center, Indianapolis, Indiana; Depart- pany, Neuroscience Research, DC 0510, Lilly Corporate Center, ment of Psychology and Psychiatry (CRY, NG), University of British Indianapolis, IN 46285. Columbia, Vancouver, BC, Canada; and Computational Neurobiol- Received May 12, 1998; revised May 27, 1998; accepted May 29, ogy Lab (JKS), The Salk Institute, La Jolla, California. 1998. NEUROPSYCHOPHARMACOLOGY 1999–VOL. 21, NO. 2 © 1999 American College of Neuropsychopharmacology Published by Elsevier Science Inc. 0893-133X/99/$–see front matter 655 Avenue of the Americas, New York, NY 10010 PII S0893-133X(98)00112-2 162 C.R. Yang et al. NEUROPSYCHOPHARMACOLOGY 1999–VOL. 21, NO. 2 1 KEY WORDS: Dopamine; Schizophrenia; Dendrites; Ca2 Channels; Persistant sodium current; Prefrontal cortex; Nuclues accumbens, GABA interneuron Schizophrenia strikes one in one hundred people worldwide, regardless of cultural or racial origins. As the illness progresses and if it remains unattended, pa- tients are frequently trapped in psychological, social, and economic devastation (Gottesman 1991; Jablensky 1995). Currently, our incomplete understanding of the neurobiological bases of schizophrenia suggests that defects in the genetic controls of brain development in such limbic regions (including temporal lobe structures such as hippocampus and the amygdala) as well as the prefrontal cortex (PFC) lead to cell loss or deformation, cytoarchitectural disorganization, and abnormal inner- vation in these brain regions (Roberts and Bruton 1990; Stevens 1992; Bogerts 1993; Shapiro 1993; Akbarian et al. 1993, 1996; Ross and Pearlson 1996; Weinberger 1996; Karayiorgou and Gogos 1997; Lewis 1997; Selemon et al. 1995, 1998). Some results from recent imaging studies of brains from living schizophrenics have suggested that there are defective functional communications between the interconnected cortical (PFC and cingulate cortex) and limbic subcortical structures (thalamus, striatum, and temporal lobe limbic structures)(see reviews of Liddle Figure 1. Schematic drawing illustrating the neuroanatom- 1996; Pfefferbaum and Marsh 1995; Andreasen 1997; ical interrelationship between amygdala, hippocampus PFC Heckers et al. 1998). Findings from these studies sug- and Nac, as well as PFC outputs to the NAc, and the A10 gest that in schizophrenics, abnormal recruitment of dopamine perikarya in the VTA. These connections provide several interconnected cortical and subcortical struc- the potential functional links by which cortical and subcorti- tures may underlie such symptom clusters as psycho- cal dopamine systems may interact. motor poverty, thought disorganization, and reality distortion (Liddle et al. 1992; Liddle 1996; Fletcher 1998; Heckers et al. 1998). lines of evidence seem to favor this hypothesis. First, As noted in Figure 1, the PFC receives converging many clinically efficacious antipsychotics are potent limbic, association cortical, and mesocortical dopamine dopamine receptor antagonists (Seeman 1992). Second, inputs. These inputs interact in the PFC and are in- dopamine receptors (Okubo et al. 1997) or the release volved functionally in high-level cognitive processes dynamics of dopamine terminals (Wong et al. 1997) are (Fuster 1995). Among the many brain regions that PFC markedly altered in living schizophrenic brains. Third, output innervates, two important subcortical regions several psychoactive substances (e.g., amphetamine, are emphasized in this review. These are the nucleus ac- phencyclidine) abnormally augment dopamine trans- cumbens (where mesoaccumbens dopamine neurons mission and induce psychotic symptoms indistinguish- terminate) and the ventral tegmental area (VTA, where able from schizophrenia. These lines of evidence have the midbrain dopamine neurons reside) (Sesack et al. provided the bases for the “Dopamine Hypothesis of 1989; Groenewegen et al. 1990; Berendse et al. 1992a, Schizophrenia” (Davis et al. 1991; Cohen and Servan- 1992b; Sesack and Pickel 1992; Gorelova and Yang Schreiber 1993; Carlson 1995). 1997b). Several of the interconnected limbic, cortical, Detailed electrophysiological mechanisms that un- and subcortical structures known to be affected in derlie the dynamic actions of neurons (i.e., in the time- schizophrenia are targets of the ascending midbrain scale of milliseconds, seconds, to minutes) in inter- dopamine systems that normally provide functional connected cortical-subcortical network of neurons are modulation of neurotransmission (Björklund and Lind- currently lacking. This review focuses primarily on the vall 1984; Mogenson et al. 1993). nature of electrophysiological actions of dopamine in Alteration of dopamine transmission in PFC and/or the PFC. It is hoped that an understanding of dopami- the nucleus accumbens has been hypothesized to be nergic actions on cortical–subcortical interactions may part of the pathophysiology of schizophrenia. Several lead to some insights into the mechanisms responsible NEUROPSYCHOPHARMACOLOGY 1999–VOL. 21, NO. 2 Prefrontal Dopamine Electrophysiology and Schizophrenia 163 for the dopamine-mediated pathophysiology of schizo- much more expanded area of innervation in primate and phrenia. Based on available electrophysiological results, human cortices, encompassing a widespread area of the we attempt to provide a neuronal model to account for sensorimotor and association cortices. In primate and certain aspects of the pathophysiology of schizophrenia. human brain, a substantial amount of tyrosine hydrox- Although outside the scope of this review, we acknowl- ylase- or dopamine-immunoreactive fibers are found in edge that other neurotransmitter/neuromodulator sys- the motor, premotor, supplementary motor area, pari- tems undoubtedly interact with the dopamine systems etal, temporal, and posterior cingulate cortices (sen- to contribute to the complex pathophysiology of schizo- sorimotor), in addition to prefrontal, anterior cingulate, phrenia. Among the neurotransmitter systems impli- insular, piriform, perirhinal, and entorhinal cortices (as- cated are those that use glutamate (Olney and Farber sociation)(Berger et al. 1988; Gaspar et al. 1989; Smiley 1995), serotonin (Iqbal and van Praag 1995; Kapur and and Goldman-Rakic 1993). Remington 1996; Busatto and Kerwin 1997; Marek
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al
    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • The Influence of Psychoactive Drugs on Brain Self-Stimulation Behaviour
    PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/147779 Please be advised that this information was generated on 2021-10-04 and may be subject to change. The influence of psychoactive drugs on brain self-stimulation behaviour A. Wauquier The influence of psychoactive drugs on brain self-stimulation behaviour A. Wauquier D/1976/1060/65 Promotores: Prof. Dr. J.M.H. VOSSEN Prof. Dr. J.M. VAN ROSSUM The influence of psychoactive drugs on brain self-stimulation behaviour Proefschrift ter verkrijging van de graad van doctor in de Sociale Wetenschappen aan de Katholieke Universiteit te Nijmegen, op gezag van de Rector Magnificus prof. dr. A.J.H. Vendrik volgens besluit van het College van Decanen in het openbaar te verdedigen op vrijdag 8 oktober 1976 des namiddags te 4.00 uur door ALBERT WAUQUIER geboren te Menen Drukkerij Daneels, Beerse, Belgium 1976 3 Aan Annie 4 Acknowledgements The author would like to thank all those who have contributed to the realization of this study whether or not they are explicitly mentioned here. The assistance of Dr. P.A.J. Janssen in providing the opportunity to perform the experiments in optimal conditions in his laboratory is grate­ fully acknowledged. His interest and suggestions have stimulated much of the present work. Dr. C.J .E. Niemegeers's constructive criticism of many of the experiments has been much appreciated. It is to him that I owe my education in the field of pharmacology.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley Et Al
    USOO6197764B1 (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley et al. (45) Date of Patent: *Mar. 6, 2001 (54) CLOZAPINE COMPOSITIONS AND USES FOREIGN PATENT DOCUMENTS THEREOF 0599 576A1 1/1994 (EP). (75) Inventors: Matthews O. Bradley, Laytonsville, 693498 1/1996 (EP). MD (US); Victor E. Shashoua, 61204136 11/1984 (JP). Belmont, MA (US); Charles S. 06-072868 3/1994 (JP). Swindell, Merion; Nigel L. Webb, 6072868 3/1994 (JP). Bryn Mawr, both of PA (US) 7082146 3/1996 (JP). 8151334 6/1996 (JP). (73) Assignee: Protarga, Inc., Conshohocken, PA (US) 9030963 2/1997 (JP). (*) Notice: Subject to any disclaimer, the term of this WO 89/07938 9/1989 (WO). patent is extended or adjusted under 35 WO 96/04001 2/1996 (WO). U.S.C. 154(b) by 0 days. WO 96/22303 7/1996 (WO). WO 96/27380 9/1996 (WO). This patent is Subject to a terminal dis WO98/17325 4/1998 (WO). claimer. OTHER PUBLICATIONS (21) Appl. No.: 08/978,541 (22) Filed: Nov. 26, 1997 Bourat, et al., "Long Chain Esters of Pipotiazine as Lon g-Acting Psychotropic Pro-Drug, Med. Chem. Proc. Int. (51) Int. Cl. .............................................. A61K 31/00 Symp. 5th (1976) pp. 105-114. (52) U.S. Cl. ........................... 514/218; 514/219; 514/220 Lohr, et al., “Neuroleptic-Induced Movement Disorders . (58) Field of Search ..................................... 514/218, 219, ..", Psychiatry, vol. 3, (1989). 514/220 Makino, et al., Chemical Abstracts, vol. 106, No. 12, (56) References Cited (90.177x) issued Mar. 23, 1987, “Pharmaceuticals Permeable to Blood-Brain Barrier'.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Targeting the Cellular Schizophrenia. Likely Employment of the Antipsychotic Agent Pimozide in Treatment of Refractory Cancers A
    Critical Reviews in Oncology / Hematology 128 (2018) 96–109 Contents lists available at ScienceDirect Critical Reviews in Oncology / Hematology journal homepage: www.elsevier.com/locate/critrevonc Targeting the cellular schizophrenia. Likely employment of the T antipsychotic agent pimozide in treatment of refractory cancers and glioblastoma ⁎ Ilhan Elmacia, Meric A. Altinozb,c, a Memorial University, Neuroacademy Group, Istanbul, Turkey b Neurooncology Branch, Neuroacademy Group, Istanbul, Turkey c Department of Psychiatry, Maastricht University, Holland, Turkey ARTICLE INFO ABSTRACT Keywords: Pimozide is currently being used in clinic as a neuroleptic and exerts versatile biological actions. Pimozide is a Pimozide cationic amphiphilic drug (CAD); CADs block the synthesis of neutral lipids, impair cholesterol homeostasis of Refractory cancers cancer cells and increase accumulation of diacylglycerol-3-phosphate. Pimozide exerts tumoricidal activity Glioblastoma which was first shown for melanoma and neuroblastoma via proposed anti- dopaminergic effects. Recently, pancreas cancers are shown to elevate dopamine receptor-2 synthesis, which is blocked by pimozide leading growth inhibition. Besides binding to inner mitochondrial membrane and reducing cellular respiration, pimozide also inhibits calmodulin, T-type calcium channels and σ-receptors which all correlate with tumor-inhibitory functions. Pimozide also exerts chemotherapy and radiotherapy-sensitizing effects in cancer cells and acts as an inhibitor of STAT-3 and STAT-5 signaling proteins with potential activity in leukemia, liver and prostate cancer. Pimozide also blocks stem cell features and Wnt-β/catenin signaling in liver cancer. Pimozide interferes with Fatty Acid Protein Binding-4 and activates PPAR-γ and it was proposed to alleviate cancer cachexia. Besides mechanisms of calmodulin and σ-receptor associated pathways, pimozide was proposed to inhibit glioblastoma via serotonin receptor 5-HT7.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al
    US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
    [Show full text]
  • Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients
    This is a repository copy of Antipsychotics for treatment of delirium in hospitalised non-ICU patients. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/132847/ Version: Published Version Article: Burry, Lisa, Mehta, S.R., Perreault, M.M et al. (6 more authors) (2018) Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews. CD005594. ISSN 1469-493X https://doi.org/10.1002/14651858.CD005594.pub3 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Antipsychotics for treatment of delirium in hospitalised non- ICU patients (Review) Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews 2018, Issue 6.
    [Show full text]
  • Zebrafish Behavioral Profiling Identifies Multi-Target Antipsychotic-Like Compounds
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE HHS Public Access provided by Carolina Digital Repository Author manuscript Author ManuscriptAuthor Manuscript Author Nat Chem Manuscript Author Biol. Author Manuscript Author manuscript; available in PMC 2016 November 30. Published in final edited form as: Nat Chem Biol. 2016 July ; 12(7): 559–566. doi:10.1038/nchembio.2097. Zebrafish behavioral profiling identifies multi-target antipsychotic-like compounds Giancarlo Bruni1,†, Andrew J. Rennekamp1,2,†, Andrea Velenich3,†, Matthew McCarroll4,5, Leo Gendelev5,9, Ethan Fertsch4,5, Jack Taylor4,5, Parth Lakhani4,5, Dennis Lensen3, Tama Evron3, Paul J. Lorello6, Xi-Ping Huang7, Sabine Kolczewski8, Galen Carey3, Barbara J. Caldarone6, Eric Prinssen8, Bryan L. Roth7, Michael J. Keiser5,9, Randall T. Peterson1,2, and David Kokel4,5 1Cardiovascular Research Center and Division of Cardiology, Department of Medicine, Massachusetts General Hospital and Department of Systems Biology, Harvard Medical School, 149 13th Street, Charlestown, Massachusetts, 02129, USA 2Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA 3Teleos Therapeutics, 196 Boston Avenue, Suite 2400, Medford, MA 02155, USA 4Department of Physiology, University of California, San Francisco, California 94158, USA 5Institute for Neurodegenerative Disease, University of California, San Francisco, California 94143, USA 6NeuroBehavior Laboratory, Harvard NeuroDiscovery Center and Department of Neurology, Brigham and Women’s Hospital, 77 Avenue
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]